NCT05429294
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior anti-HER2 therapy & chemotherapy in the metastatic setting; Patients with central nervous system metastasis
https://ClinicalTrials.gov/show/NCT05429294